Exelixis
EXEL
#2109
Rank
NZ$12.18 B
Marketcap
$42.70
Share price
-1.53%
Change (1 day)
18.19%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total assets

Total assets on the balance sheet as of June 2024 : NZ$4.48 B

According to Exelixis's latest financial reports the company's total assets are NZ$4.48 B. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

Exelixis - Total assets on balance sheet (from 2001 to 2024)

Total assets by year

Year Total assets Change
2023-12-31NZ$4.65 B-3.83%
2022-12-31NZ$4.83 B26.64%
2021-12-31NZ$3.82 B28.55%
2020-12-31NZ$2.97 B6.31%
2019-12-31NZ$2.79 B31.9%
2018-12-31NZ$2.11 B129.7%
2017-12-31NZ$0.92 B7.28%
2016-12-31NZ$0.86 B76.91%
2015-12-31NZ$0.48 B17.97%
2014-12-31NZ$0.41 B-32.75%
2013-12-31NZ$0.61 B-30.33%
2012-12-31NZ$0.87 B74.55%
2011-12-31NZ$0.50 B7.32%
2010-12-31NZ$0.46 B-1.42%
2009-12-31NZ$0.47 B-31.58%
2008-12-31NZ$0.69 B30.53%
2007-12-31NZ$0.53 B-4.97%
2006-12-31NZ$0.56 B15.3%
2005-12-31NZ$0.48 B19.22%
2004-12-31NZ$0.40 B-25.82%
2003-12-31NZ$0.55 B-15.06%
2002-12-31NZ$0.64 B-22.37%
2001-12-31NZ$0.83 B

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
NZ$118.75 B 2,549.29%๐Ÿ‡ฌ๐Ÿ‡ง UK
NZ$224.82 B 4,915.83%๐Ÿ‡ซ๐Ÿ‡ท France
NZ$182.05 B 3,961.49%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$152.98 B 3,312.98%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$146.93 B 3,178.15%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$292.70 B 6,430.12%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$349.44 B 7,696.02%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$81.48 M-98.18%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.16 B-96.35%๐Ÿ‡บ๐Ÿ‡ธ USA